DSIP
Also known as: Delta Sleep-Inducing Peptide
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide studied for reported effects on sleep and stress. It is a research peptide and is not approved for human use.
- Category
- Sleep / Neuropeptide
- Reported half-life
- Not well established
- Common forms
- Lyophilised powder for reconstitution, Research-grade solution
- Research status
- Studied since the 1970s in mostly small and older investigations; not approved for human use in Australia. The evidence base is limited and inconsistent.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in early research to influence sleep patterns
- Studied for possible effects on stress and the stress-hormone axis
- Reported to interact with neuroendocrine regulation in animal models
- Reported to have possible antioxidant-related effects in laboratory studies
How it is reported to work
DSIP is a short naturally occurring neuropeptide first described in connection with delta-wave sleep. Its precise mechanism is not well defined; it is proposed to influence neuroendocrine and stress-related signalling. The reported effects derive mainly from older animal studies and small human investigations, and findings have been inconsistent.
Background
DSIP, or Delta Sleep-Inducing Peptide, is a naturally occurring neuropeptide first identified in the 1970s in connection with deep (delta-wave) sleep. It has since been studied in a range of sleep and stress contexts. This page is educational information, not medical advice, and the effects below are reported claims, not established facts.
What the research shows
DSIP research is largely older and inconsistent, made up of small animal and human studies. Despite its name, evidence that it reliably induces sleep in humans is limited and contested, and it has not been validated in robust modern trials.
| Evidence type | Status |
|---|---|
| Older / small studies | Present |
| Robust modern human trials | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, people report interest in DSIP for sleep and stress. These are anecdotal reports without validated human outcomes. Reported benefits should not be read as proven, and nothing here is encouragement to use it.
Things to be aware of
DSIP is not approved for human use in Australia, and its human evidence base is limited and inconsistent. Long-term safety is not characterised, and grey-market preparations cannot be verified for purity or identity. If you have a sleep or other health concern, the appropriate step is to consult a qualified healthcare professional. This article does not recommend obtaining or using DSIP.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported by users to be associated with easier sleep onset and deeper sleep
- Reported in early research to influence sleep patterns
- Reported to be studied for effects on stress and the stress-hormone axis
- Reported to be associated with a calmer or more relaxed state
- Reported to have possible antioxidant-related effects in laboratory studies
Common side effects
- Reported next-day grogginess or drowsiness
- Reported injection-site redness or irritation
- Reported headache
- Reported vivid dreams or disrupted sleep timing in some reports
Rare / serious side effects
- Reported allergic or hypersensitivity reactions to unverified preparations
- Reported infection risk from non-sterile reconstitution and injection
- Unknown long-term effects, as human data is limited and inconsistent
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of DSIP. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-injection of unregulated grey-market powder of unverified purity or identity
- Reported combining with alcohol or sedatives, risking compounded drowsiness
- Reported escalating doses chasing stronger sleep effects despite inconsistent evidence
- Reported substitution of medical assessment of a sleep disorder with this unapproved peptide
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Users report possible effects on sleep onset the same night to within a few days, though research findings are inconsistent.
First effects
Some report changes in sleep onset the same night or within a few days
Noticeable change
Reported sleep-quality changes over the first weeks of reported use
Clear results
Any reported sustained sleep changes described over several weeks, with inconsistent evidence
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take DSIP. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous (SubQ) injection |
|---|---|
| Typical reported dose | Reported at roughly 100–300 mcg |
| Frequency | Reported once at night, before sleep |
| Cycle length | Reported as occasional or short-term use; protocols are not well established |
Reported reconstitution (mg → units)
Example only: a 5 mg vial reconstituted with 2.5 mL of bacteriostatic water gives 2 mg/mL (2000 mcg/mL). A 200 mcg dose is about 0.1 mL (10 units on a U-100 syringe); a 100 mcg dose is about 0.05 mL (5 units).
Work out the units for your vial → CalculatorReported use is commonly described as dosing in the evening for short stretches rather than continuously. This is reported information about patterns of use, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
DSIP is not approved for human use in Australia and has limited, inconsistent human safety data. Its long-term effects are not characterised, and grey-market preparations cannot be verified for purity or identity. Anyone with a sleep or other health concern should consult a qualified healthcare professional rather than self-experiment.